Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Monthly Newsletter
Edition: December 2025
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Notable Podcast: Drug Fix: Understanding the US FDA’s CDER Leadership Shuffle
- Notable Webinar: 2026 Preview Webinar (Jan 22, 2026)
- Notable Webinar: Inside #JPM2026: The Stories Behind the Summit (Feb 5, 2026)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- Notable M&A: BioMarin to Acquire Amicus Therapeutics for $4.8B
- Notable M&A: Sanofi to Acquire Dynavax for $2.2B
- Notable Licensing: Pfizer Enters into Exclusive Collaboration and License Agreement with Fosun Pharma’s YaoPharma for GLP-1R Agonist YP05002 totalling $2.1B
- Notable Licensing: Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 totalling $2B
- Notable Financing: Syremis Therapeutics Raises $165M in Series A Round
- Notable Financing: Medline Nets $6.1B in Upsized IPO
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Notable Analysis: BeOne Medicines | BGB-16673 | CLL (Phase 3): “BeOne's BGB-16673 matches bexobrutideg on response rates in heavily pre-treated CLL but loses out on safety profile…”
- Notable Analysis: Galapagos | GLPG5101 | Mantle Cell Lymphoma (Phase 2): “GLPG5101 continues to impress in mantle cell lymphoma despite the windup of Galapagos' cell therapy unit…”
- Notable Analysis: Ultragenyx | BPS804 | Osteogenesis Imperfecta (Phase 3): “Setrusumab Fails in Pivotal Trials for Osteogenesis Imperfecta, Casting Doubt on Future Development…”
- Notable Analysis: uniQure | AMT-130 | Huntington's Disease (Phase 2): “FDA deems AMT-130 BLA data insufficient, leaving path forward in Huntington's disease unclear…”
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Notable Report: 2025 Post-ASH Report
- Notable Report: In Vivo Outlook 2026
- Notable Report: 2026 Investor & Medical Conference Calendar
- Notable Report: Epi & Market Forecast: Amyotrophic Lateral Sclerosis (ALS)
- Notable Report: Epi & Market Forecast: Autism Spectrum Disorders
- Notable Report: Epi & Market Forecast: Cervical Cancer
- Notable Report: Epi & Market Forecast: Glioblastoma
- Notable Report: KOL Interview: Schizophrenia | ALS | Spinal Muscular Atrophy | Systemic Lupus Erythematosus
Latest Editorial Podcasts
